Psychedelic Psychiatry's Brave New World.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32243793.
- Also identified by DOI 10.1016/j.cell.2020.03.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Medical subject headings
- Hallucinogens
- Mental Disorders
- Psilocybin
- Serotonin 5-HT2 Receptor Agonists